Starling Oncology, Inc. (STLN) stock
STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
$3.40−0.14 (-3.95%)
Close on Nov 17, 2026Market cap $346.51MP/E –Yield –
Starling Oncology price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Starling Oncology's price to sales ratio was 0.7× on Nov 11, 2026, against 0.7× a year earlier. Over the last 5 years it ranged from 0.0× to 3.2×, with a median of 0.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.7× | −0.0 |
| 2025 | Dec 31, 2025 | 0.8× | +0.7 |
| 2024 | Dec 31, 2024 | 0.1× | −0.4 |
| 2023 | Dec 29, 2023 | 0.5× | −0.0 |
| 2022 | Dec 30, 2022 | 0.5× | – |
See a number that looks wrong?